APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Chagas Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Chagas Disease Drug Market Analysis and Forecast 2026-2032

Report ID 173976730222 December 2025197 pages

Choose your research edition.

Industry ResearchChagas Disease Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Chagas Disease Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Chagas Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chagas Disease Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Chagas Disease Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Chagas Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Chagas Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Chagas Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Chagas Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Chagas Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Chagas Disease Drug include Eisai Co Ltd, Sanofi, Novartis AG, GlaxoSmithKline Plc, Bayer AG, AstraZeneca Plc, Oblita Therapeutics BVBA, Merck & Co Inc and Kancera AB, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Chagas Disease Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Chagas Disease Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Chagas Disease Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Chagas Disease Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Chagas Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Chagas Disease Drug sales, projected growth trends, production technology, application and end-user industry.

Chagas Disease Drug Segment by Company

Eisai Co Ltd

Sanofi

Novartis AG

GlaxoSmithKline Plc

Bayer AG

AstraZeneca Plc

Oblita Therapeutics BVBA

Merck & Co Inc

Kancera AB

Humanigen Inc

Grupo Praxis Pharmaceutical SA

Daiichi Sankyo Co Ltd

Chagas Disease Drug Segment by Type

Cz-007

Cz-008

D-121

DNDI-0690

EPLBS-1246

EPLBS-967

Others

Chagas Disease Drug Segment by Application

Hospital

Clinic

Others

Chagas Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chagas Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chagas Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chagas Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Chagas Disease Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Chagas Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chagas Disease Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Chagas Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cz-007 Major Manufacturers Table 3. Cz-008 Major Manufacturers Table 4. D-121 Major Manufacturers Table 5. DNDI-0690 Major Manufacturers Table 6. EPLBS-1246 Major Manufacturers Table 7. EPLBS-967 Major Manufacturers Table 8. Others Major Manufacturers Table 9. Global Chagas Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Hospital Major Manufacturers Table 11. Clinic Major Manufacturers Table 12. Others Major Manufacturers Table 13. Chagas Disease Drug Industry Trends Table 14. Chagas Disease Drug Industry Drivers Table 15. Chagas Disease Drug Industry Opportunities and Challenges Table 16. Chagas Disease Drug Industry Restraints Table 17. Global Chagas Disease Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Chagas Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Chagas Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Chagas Disease Drug Revenue Market Share by Region (2021-2026) Table 21. Global Chagas Disease Drug Revenue Market Share by Region (2027-2032) Table 22. Global Chagas Disease Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 23. Global Chagas Disease Drug Sales by Region (2021-2026) & (k units) Table 24. Global Chagas Disease Drug Sales by Region (2027-2032) & (k units) Table 25. Global Chagas Disease Drug Sales Market Share by Region (2021-2026) Table 26. Global Chagas Disease Drug Sales Market Share by Region (2027-2032) Table 27. Global Chagas Disease Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Chagas Disease Drug Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Chagas Disease Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Chagas Disease Drug Sales Market Share by Manufacturers (2021-2026) Table 31. Global Chagas Disease Drug Sales Price (US$/unit) of Manufacturers (2021-2026) Table 32. Global Chagas Disease Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Chagas Disease Drug Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Chagas Disease Drug Manufacturers, Product Type & Application Table 35. Global Chagas Disease Drug Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Chagas Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Chagas Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Chagas Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Chagas Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Chagas Disease Drug Revenue Market Share by Type (2021-2026) Table 42. Global Chagas Disease Drug Revenue Market Share by Type (2027-2032) Table 43. Global Chagas Disease Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 44. Global Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 45. Global Chagas Disease Drug Sales by Type (2027-2032) & (k units) Table 46. Global Chagas Disease Drug Sales Market Share by Type (2021-2026) Table 47. Global Chagas Disease Drug Sales Market Share by Type (2027-2032) Table 48. Global Chagas Disease Drug Price by Type (2021-2026) & (US$/unit) Table 49. Global Chagas Disease Drug Price by Type (2027-2032) & (US$/unit) Table 50. Global Chagas Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Chagas Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Chagas Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Chagas Disease Drug Revenue Market Share by Application (2021-2026) Table 54. Global Chagas Disease Drug Revenue Market Share by Application (2027-2032) Table 55. Global Chagas Disease Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 56. Global Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 57. Global Chagas Disease Drug Sales by Application (2027-2032) & (k units) Table 58. Global Chagas Disease Drug Sales Market Share by Application (2021-2026) Table 59. Global Chagas Disease Drug Sales Market Share by Application (2027-2032) Table 60. Global Chagas Disease Drug Price by Application (2021-2026) & (US$/unit) Table 61. Global Chagas Disease Drug Price by Application (2027-2032) & (US$/unit) Table 62. Eisai Co Ltd Company Information Table 63. Eisai Co Ltd Business Overview Table 64. Eisai Co Ltd Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Eisai Co Ltd Chagas Disease Drug Product Portfolio Table 66. Eisai Co Ltd Recent Development Table 67. Sanofi Company Information Table 68. Sanofi Business Overview Table 69. Sanofi Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Sanofi Chagas Disease Drug Product Portfolio Table 71. Sanofi Recent Development Table 72. Novartis AG Company Information Table 73. Novartis AG Business Overview Table 74. Novartis AG Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Novartis AG Chagas Disease Drug Product Portfolio Table 76. Novartis AG Recent Development Table 77. GlaxoSmithKline Plc Company Information Table 78. GlaxoSmithKline Plc Business Overview Table 79. GlaxoSmithKline Plc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. GlaxoSmithKline Plc Chagas Disease Drug Product Portfolio Table 81. GlaxoSmithKline Plc Recent Development Table 82. Bayer AG Company Information Table 83. Bayer AG Business Overview Table 84. Bayer AG Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Bayer AG Chagas Disease Drug Product Portfolio Table 86. Bayer AG Recent Development Table 87. AstraZeneca Plc Company Information Table 88. AstraZeneca Plc Business Overview Table 89. AstraZeneca Plc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. AstraZeneca Plc Chagas Disease Drug Product Portfolio Table 91. AstraZeneca Plc Recent Development Table 92. Oblita Therapeutics BVBA Company Information Table 93. Oblita Therapeutics BVBA Business Overview Table 94. Oblita Therapeutics BVBA Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Oblita Therapeutics BVBA Chagas Disease Drug Product Portfolio Table 96. Oblita Therapeutics BVBA Recent Development Table 97. Merck & Co Inc Company Information Table 98. Merck & Co Inc Business Overview Table 99. Merck & Co Inc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Merck & Co Inc Chagas Disease Drug Product Portfolio Table 101. Merck & Co Inc Recent Development Table 102. Kancera AB Company Information Table 103. Kancera AB Business Overview Table 104. Kancera AB Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Kancera AB Chagas Disease Drug Product Portfolio Table 106. Kancera AB Recent Development Table 107. Humanigen Inc Company Information Table 108. Humanigen Inc Business Overview Table 109. Humanigen Inc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Humanigen Inc Chagas Disease Drug Product Portfolio Table 111. Humanigen Inc Recent Development Table 112. Grupo Praxis Pharmaceutical SA Company Information Table 113. Grupo Praxis Pharmaceutical SA Business Overview Table 114. Grupo Praxis Pharmaceutical SA Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Grupo Praxis Pharmaceutical SA Chagas Disease Drug Product Portfolio Table 116. Grupo Praxis Pharmaceutical SA Recent Development Table 117. Daiichi Sankyo Co Ltd Company Information Table 118. Daiichi Sankyo Co Ltd Business Overview Table 119. Daiichi Sankyo Co Ltd Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Daiichi Sankyo Co Ltd Chagas Disease Drug Product Portfolio Table 121. Daiichi Sankyo Co Ltd Recent Development Table 122. North America Chagas Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 123. North America Chagas Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 124. North America Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 125. North America Chagas Disease Drug Sales by Type (2027-2032) & (k units) Table 126. North America Chagas Disease Drug Sales Price by Type (2021-2026) & (US$/unit) Table 127. North America Chagas Disease Drug Sales Price by Type (2027-2032) & (US$/unit) Table 128. North America Chagas Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 129. North America Chagas Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 130. North America Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 131. North America Chagas Disease Drug Sales by Application (2027-2032) & (k units) Table 132. North America Chagas Disease Drug Sales Price by Application (2021-2026) & (US$/unit) Table 133. North America Chagas Disease Drug Sales Price by Application (2027-2032) & (US$/unit) Table 134. North America Chagas Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. North America Chagas Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 136. North America Chagas Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 137. North America Chagas Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 138. North America Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 139. North America Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 140. North America Chagas Disease Drug Sales Price by Country (2021-2026) & (US$/unit) Table 141. North America Chagas Disease Drug Sales Price by Country (2027-2032) & (US$/unit) Table 142. United States Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 143. Canada Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 144. Mexico Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 145. Europe Chagas Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 146. Europe Chagas Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 147. Europe Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 148. Europe Chagas Disease Drug Sales by Type (2027-2032) & (k units) Table 149. Europe Chagas Disease Drug Sales Price by Type (2021-2026) & (US$/unit) Table 150. Europe Chagas Disease Drug Sales Price by Type (2027-2032) & (US$/unit) Table 151. Europe Chagas Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 152. Europe Chagas Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 153. Europe Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 154. Europe Chagas Disease Drug Sales by Application (2027-2032) & (k units) Table 155. Europe Chagas Disease Drug Sales Price by Application (2021-2026) & (US$/unit) Table 156. Europe Chagas Disease Drug Sales Price by Application (2027-2032) & (US$/unit) Table 157. Europe Chagas Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Europe Chagas Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 159. Europe Chagas Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 160. Europe Chagas Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 161. Europe Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 162. Europe Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 163. Europe Chagas Disease Drug Sales Price by Country (2021-2026) & (US$/unit) Table 164. Europe Chagas Disease Drug Sales Price by Country (2027-2032) & (US$/unit) Table 165. Germany Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 166. France Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 167. U.K. Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 168. Italy Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 169. Russia Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 170. Spain Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 171. Netherlands Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 172. Switzerland Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 173. Sweden Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 174. Poland Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 175. China Chagas Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 176. China Chagas Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 177. China Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 178. China Chagas Disease Drug Sales by Type (2027-2032) & (k units) Table 179. China Chagas Disease Drug Sales Price by Type (2021-2026) & (US$/unit) Table 180. China Chagas Disease Drug Sales Price by Type (2027-2032) & (US$/unit) Table 181. China Chagas Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 182. China Chagas Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 183. China Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 184. China Chagas Disease Drug Sales by Application (2027-2032) & (k units) Table 185. China Chagas Disease Drug Sales Price by Application (2021-2026) & (US$/unit) Table 186. China Chagas Disease Drug Sales Price by Application (2027-2032) & (US$/unit) Table 187. Asia Chagas Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 188. Asia Chagas Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 189. Asia Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 190. Asia Chagas Disease Drug Sales by Type (2027-2032) & (k units) Table 191. Asia Chagas Disease Drug Sales Price by Type (2021-2026) & (US$/unit) Table 192. Asia Chagas Disease Drug Sales Price by Type (2027-2032) & (US$/unit) Table 193. Asia Chagas Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 194. Asia Chagas Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 195. Asia Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 196. Asia Chagas Disease Drug Sales by Application (2027-2032) & (k units) Table 197. Asia Chagas Disease Drug Sales Price by Application (2021-2026) & (US$/unit) Table 198. Asia Chagas Disease Drug Sales Price by Application (2027-2032) & (US$/unit) Table 199. Asia Chagas Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. Asia Chagas Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 201. Asia Chagas Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 202. Asia Chagas Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 203. Asia Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 204. Asia Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 205. Asia Chagas Disease Drug Sales Price by Country (2021-2026) & (US$/unit) Table 206. Asia Chagas Disease Drug Sales Price by Country (2027-2032) & (US$/unit) Table 207. Japan Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 208. South Korea Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 209. India Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 210. Australia Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 211. Taiwan Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 212. Southeast Asia Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 213. SAMEA Chagas Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 214. SAMEA Chagas Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 215. SAMEA Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 216. SAMEA Chagas Disease Drug Sales by Type (2027-2032) & (k units) Table 217. SAMEA Chagas Disease Drug Sales Price by Type (2021-2026) & (US$/unit) Table 218. SAMEA Chagas Disease Drug Sales Price by Type (2027-2032) & (US$/unit) Table 219. SAMEA Chagas Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 220. SAMEA Chagas Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 221. SAMEA Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 222. SAMEA Chagas Disease Drug Sales by Application (2027-2032) & (k units) Table 223. SAMEA Chagas Disease Drug Sales Price by Application (2021-2026) & (US$/unit) Table 224. SAMEA Chagas Disease Drug Sales Price by Application (2027-2032) & (US$/unit) Table 225. SAMEA Chagas Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 226. SAMEA Chagas Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 227. SAMEA Chagas Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 228. SAMEA Chagas Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 229. SAMEA Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 230. SAMEA Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 231. SAMEA Chagas Disease Drug Sales Price by Country (2021-2026) & (US$/unit) Table 232. SAMEA Chagas Disease Drug Sales Price by Country (2027-2032) & (US$/unit) Table 233. Brazil Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 234. Argentina Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 235. Chile Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 236. Colombia Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 237. Peru Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 238. Saudi Arabia Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 239. Israel Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 240. UAE Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 241. Turkey Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 242. Iran Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 243. Egypt Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Table 244. Key Raw Materials Table 245. Raw Materials Key Suppliers Table 246. Chagas Disease Drug Distributors List Table 247. Chagas Disease Drug Customers List Table 248. Research Programs/Design for This Report Table 249. Authors List of This Report Table 250. Secondary Sources Table 251. Primary Sources List of Figures Figure 1. Chagas Disease Drug Image Figure 2. Global Chagas Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chagas Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cz-007 Image Figure 5. Cz-008 Image Figure 6. D-121 Image Figure 7. DNDI-0690 Image Figure 8. EPLBS-1246 Image Figure 9. EPLBS-967 Image Figure 10. Others Image Figure 11. Global Chagas Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Chagas Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Others Image Figure 16. Global Chagas Disease Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Chagas Disease Drug Revenue (2021-2032) & (US$ Million) Figure 18. Global Chagas Disease Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Chagas Disease Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Chagas Disease Drug Revenue Market Share by Region (2021-2032) Figure 21. Global Chagas Disease Drug Sales (2021-2032) & (k units) Figure 22. Global Chagas Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 23. Global Chagas Disease Drug Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Chagas Disease Drug Sales YoY (2021-2032) & (k units) Figure 25. Europe Chagas Disease Drug Sales YoY (2021-2032) & (k units) Figure 26. China Chagas Disease Drug Sales YoY (2021-2032) & (k units) Figure 27. Asia (Excluding China) Chagas Disease Drug Sales YoY (2021-2032) & (k units) Figure 28. South America, Middle East and Africa Chagas Disease Drug Sales YoY (2021-2032) & (k units) Figure 29. Global Chagas Disease Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Chagas Disease Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Chagas Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Chagas Disease Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Chagas Disease Drug Revenue Market Share by Type (2021-2032) Figure 35. Global Chagas Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 36. Global Chagas Disease Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Chagas Disease Drug Sales Market Share by Type (2021-2032) Figure 38. Global Chagas Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Chagas Disease Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Chagas Disease Drug Revenue Market Share by Application (2021-2032) Figure 41. Global Chagas Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 42. Global Chagas Disease Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Chagas Disease Drug Sales Market Share by Application (2021-2032) Figure 44. North America Chagas Disease Drug Revenue Share by Type (2021-2032) Figure 45. North America Chagas Disease Drug Sales Share by Type (2021-2032) Figure 46. North America Chagas Disease Drug Revenue Share by Application (2021-2032) Figure 47. North America Chagas Disease Drug Sales Share by Application (2021-2032) Figure 48. North America Chagas Disease Drug Revenue Share by Country (2021-2032) Figure 49. North America Chagas Disease Drug Sales Share by Country (2021-2032) Figure 50. Europe Chagas Disease Drug Revenue Share by Type (2021-2032) Figure 51. Europe Chagas Disease Drug Sales Share by Type (2021-2032) Figure 52. Europe Chagas Disease Drug Revenue Share by Application (2021-2032) Figure 53. Europe Chagas Disease Drug Sales Share by Application (2021-2032) Figure 54. Europe Chagas Disease Drug Revenue Share by Country (2021-2032) Figure 55. Europe Chagas Disease Drug Sales Share by Country (2021-2032) Figure 56. China Chagas Disease Drug Revenue Share by Type (2021-2032) Figure 57. China Chagas Disease Drug Sales Share by Type (2021-2032) Figure 58. China Chagas Disease Drug Revenue Share by Application (2021-2032) Figure 59. China Chagas Disease Drug Sales Share by Application (2021-2032) Figure 60. Asia Chagas Disease Drug Revenue Share by Type (2021-2032) Figure 61. Asia Chagas Disease Drug Sales Share by Type (2021-2032) Figure 62. Asia Chagas Disease Drug Revenue Share by Application (2021-2032) Figure 63. Asia Chagas Disease Drug Sales Share by Application (2021-2032) Figure 64. Asia Chagas Disease Drug Revenue Share by Country (2021-2032) Figure 65. Asia Chagas Disease Drug Sales Share by Country (2021-2032) Figure 66. SAMEA Chagas Disease Drug Revenue Share by Type (2021-2032) Figure 67. SAMEA Chagas Disease Drug Sales Share by Type (2021-2032) Figure 68. SAMEA Chagas Disease Drug Revenue Share by Application (2021-2032) Figure 69. SAMEA Chagas Disease Drug Sales Share by Application (2021-2032) Figure 70. SAMEA Chagas Disease Drug Revenue Share by Country (2021-2032) Figure 71. SAMEA Chagas Disease Drug Sales Share by Country (2021-2032) Figure 72. Chagas Disease Drug Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Chagas Disease Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Cz-007
  • Cz-008
  • D-121
  • DNDI-0690
  • EPLBS-1246
  • EPLBS-967
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Eisai Co Ltd
  • Sanofi
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG
  • AstraZeneca Plc
  • Oblita Therapeutics BVBA
  • Merck & Co Inc
  • Kancera AB
  • Humanigen Inc
  • Grupo Praxis Pharmaceutical SA
  • Daiichi Sankyo Co Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Chagas Disease Drug Market by Type
  3. 1.2.1 Global Chagas Disease Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cz-007
  5. 1.2.3 Cz-008
  6. 1.2.4 D-121
  7. 1.2.5 DNDI-0690
  8. 1.2.6 EPLBS-1246
  9. 1.2.7 EPLBS-967
  10. 1.2.8 Others
  11. 1.3 Chagas Disease Drug Market by Application
  12. 1.3.1 Global Chagas Disease Drug Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Hospital
  14. 1.3.3 Clinic
  15. 1.3.4 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Chagas Disease Drug Market Dynamics
  1. 2.1 Chagas Disease Drug Industry Trends
  2. 2.2 Chagas Disease Drug Industry Drivers
  3. 2.3 Chagas Disease Drug Industry Opportunities and Challenges
  4. 2.4 Chagas Disease Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Chagas Disease Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Chagas Disease Drug Revenue by Region
  3. 3.2.1 Global Chagas Disease Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Chagas Disease Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Chagas Disease Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Chagas Disease Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Chagas Disease Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Chagas Disease Drug Sales by Region
  9. 3.4.1 Global Chagas Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Chagas Disease Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Chagas Disease Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Chagas Disease Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Chagas Disease Drug Revenue by Manufacturers
  2. 4.1.1 Global Chagas Disease Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Chagas Disease Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Chagas Disease Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Chagas Disease Drug Sales by Manufacturers
  6. 4.2.1 Global Chagas Disease Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Chagas Disease Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Chagas Disease Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Chagas Disease Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Chagas Disease Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Chagas Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Chagas Disease Drug Manufacturers, Product Type & Application
  13. 4.7 Global Chagas Disease Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Chagas Disease Drug Market CR5 and HHI
  16. 4.8.2 2025 Chagas Disease Drug Tier 1, Tier 2, and Tier 3
5 Chagas Disease Drug Market by Type
  1. 5.1 Global Chagas Disease Drug Revenue by Type
  2. 5.1.1 Global Chagas Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Chagas Disease Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Chagas Disease Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Chagas Disease Drug Sales by Type
  6. 5.2.1 Global Chagas Disease Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chagas Disease Drug Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Chagas Disease Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Chagas Disease Drug Price by Type
6 Chagas Disease Drug Market by Application
  1. 6.1 Global Chagas Disease Drug Revenue by Application
  2. 6.1.1 Global Chagas Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Chagas Disease Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Chagas Disease Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Chagas Disease Drug Sales by Application
  6. 6.2.1 Global Chagas Disease Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Chagas Disease Drug Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Chagas Disease Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Chagas Disease Drug Price by Application
7 Company Profiles
  1. 7.1 Eisai Co Ltd
  2. 7.1.1 Eisai Co Ltd Company Information
  3. 7.1.2 Eisai Co Ltd Business Overview
  4. 7.1.3 Eisai Co Ltd Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Eisai Co Ltd Chagas Disease Drug Product Portfolio
  6. 7.1.5 Eisai Co Ltd Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Chagas Disease Drug Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Novartis AG
  14. 7.3.1 Novartis AG Company Information
  15. 7.3.2 Novartis AG Business Overview
  16. 7.3.3 Novartis AG Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novartis AG Chagas Disease Drug Product Portfolio
  18. 7.3.5 Novartis AG Recent Developments
  19. 7.4 GlaxoSmithKline Plc
  20. 7.4.1 GlaxoSmithKline Plc Company Information
  21. 7.4.2 GlaxoSmithKline Plc Business Overview
  22. 7.4.3 GlaxoSmithKline Plc Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Plc Chagas Disease Drug Product Portfolio
  24. 7.4.5 GlaxoSmithKline Plc Recent Developments
  25. 7.5 Bayer AG
  26. 7.5.1 Bayer AG Company Information
  27. 7.5.2 Bayer AG Business Overview
  28. 7.5.3 Bayer AG Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Bayer AG Chagas Disease Drug Product Portfolio
  30. 7.5.5 Bayer AG Recent Developments
  31. 7.6 AstraZeneca Plc
  32. 7.6.1 AstraZeneca Plc Company Information
  33. 7.6.2 AstraZeneca Plc Business Overview
  34. 7.6.3 AstraZeneca Plc Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca Plc Chagas Disease Drug Product Portfolio
  36. 7.6.5 AstraZeneca Plc Recent Developments
  37. 7.7 Oblita Therapeutics BVBA
  38. 7.7.1 Oblita Therapeutics BVBA Company Information
  39. 7.7.2 Oblita Therapeutics BVBA Business Overview
  40. 7.7.3 Oblita Therapeutics BVBA Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Oblita Therapeutics BVBA Chagas Disease Drug Product Portfolio
  42. 7.7.5 Oblita Therapeutics BVBA Recent Developments
  43. 7.8 Merck & Co Inc
  44. 7.8.1 Merck & Co Inc Company Information
  45. 7.8.2 Merck & Co Inc Business Overview
  46. 7.8.3 Merck & Co Inc Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Merck & Co Inc Chagas Disease Drug Product Portfolio
  48. 7.8.5 Merck & Co Inc Recent Developments
  49. 7.9 Kancera AB
  50. 7.9.1 Kancera AB Company Information
  51. 7.9.2 Kancera AB Business Overview
  52. 7.9.3 Kancera AB Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Kancera AB Chagas Disease Drug Product Portfolio
  54. 7.9.5 Kancera AB Recent Developments
  55. 7.10 Humanigen Inc
  56. 7.10.1 Humanigen Inc Company Information
  57. 7.10.2 Humanigen Inc Business Overview
  58. 7.10.3 Humanigen Inc Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Humanigen Inc Chagas Disease Drug Product Portfolio
  60. 7.10.5 Humanigen Inc Recent Developments
  61. 7.11 Grupo Praxis Pharmaceutical SA
  62. 7.11.1 Grupo Praxis Pharmaceutical SA Company Information
  63. 7.11.2 Grupo Praxis Pharmaceutical SA Business Overview
  64. 7.11.3 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Product Portfolio
  66. 7.11.5 Grupo Praxis Pharmaceutical SA Recent Developments
  67. 7.12 Daiichi Sankyo Co Ltd
  68. 7.12.1 Daiichi Sankyo Co Ltd Company Information
  69. 7.12.2 Daiichi Sankyo Co Ltd Business Overview
  70. 7.12.3 Daiichi Sankyo Co Ltd Chagas Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Daiichi Sankyo Co Ltd Chagas Disease Drug Product Portfolio
  72. 7.12.5 Daiichi Sankyo Co Ltd Recent Developments
8 North America
  1. 8.1 North America Chagas Disease Drug Market Size by Type
  2. 8.1.1 North America Chagas Disease Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Chagas Disease Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Chagas Disease Drug Price by Type (2021-2032)
  5. 8.2 North America Chagas Disease Drug Market Size by Application
  6. 8.2.1 North America Chagas Disease Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Chagas Disease Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Chagas Disease Drug Price by Application (2021-2032)
  9. 8.3 North America Chagas Disease Drug Market Size by Country
  10. 8.3.1 North America Chagas Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Chagas Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Chagas Disease Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Chagas Disease Drug Market Size by Type
  2. 9.1.1 Europe Chagas Disease Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Chagas Disease Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Chagas Disease Drug Price by Type (2021-2032)
  5. 9.2 Europe Chagas Disease Drug Market Size by Application
  6. 9.2.1 Europe Chagas Disease Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Chagas Disease Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Chagas Disease Drug Price by Application (2021-2032)
  9. 9.3 Europe Chagas Disease Drug Market Size by Country
  10. 9.3.1 Europe Chagas Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Chagas Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Chagas Disease Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Chagas Disease Drug Market Size by Type
  2. 10.1.1 China Chagas Disease Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Chagas Disease Drug Sales by Type (2021-2032)
  4. 10.1.3 China Chagas Disease Drug Price by Type (2021-2032)
  5. 10.2 China Chagas Disease Drug Market Size by Application
  6. 10.2.1 China Chagas Disease Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Chagas Disease Drug Sales by Application (2021-2032)
  8. 10.2.3 China Chagas Disease Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Chagas Disease Drug Market Size by Type
  2. 11.1.1 Asia Chagas Disease Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Chagas Disease Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Chagas Disease Drug Price by Type (2021-2032)
  5. 11.2 Asia Chagas Disease Drug Market Size by Application
  6. 11.2.1 Asia Chagas Disease Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Chagas Disease Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Chagas Disease Drug Price by Application (2021-2032)
  9. 11.3 Asia Chagas Disease Drug Market Size by Country
  10. 11.3.1 Asia Chagas Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Chagas Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Chagas Disease Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Chagas Disease Drug Market Size by Type
  2. 12.1.1 SAMEA Chagas Disease Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Chagas Disease Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Chagas Disease Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Chagas Disease Drug Market Size by Application
  6. 12.2.1 SAMEA Chagas Disease Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Chagas Disease Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Chagas Disease Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Chagas Disease Drug Market Size by Country
  10. 12.3.1 SAMEA Chagas Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Chagas Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Chagas Disease Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Chagas Disease Drug Value Chain Analysis
  2. 13.1.1 Chagas Disease Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Chagas Disease Drug Production Mode & Process
  6. 13.2 Chagas Disease Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Chagas Disease Drug Distributors
  9. 13.2.3 Chagas Disease Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst